TNFRSF8 and Hodgkins lymphoma: Brentuximab vedotin—an anti-CD30 antibody conjugated to antimicrotubule agent, monomethyl auristatin E—showed ORR of 75% and CR rate of 34% in heavily pretreated patients with HL after autoHCT [22].